Medical Applications of Beta-Glucan

Beta Glucan in Treatment of Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Diseases (IBD): Ulcerative Colitis (UC) and Crohn's Disease (CD)

Author(s): Betül Gürünlü

Pp: 81-92 (12)

DOI: 10.2174/9789815039238122010011

* (Excluding Mailing and Handling)


Since ancient times, the healing properties of fungi have been used in the
treatment of many health problems such as hypertension, diabetes, allergies, cancer,
atherosclerosis, digestive system disorders and inflammation. Inflammatory bowel
diseases are a very serious health problem that significantly reduces a person's quality
of life. Regarding immune-mediated inflammatory diseases, two of the most common
types of inflammatory bowel disease are Crohn's disease (CD) and ulcerative colitis
(UC). Levels of C reactive protein (CRP), neutrophil elastase, leukocyte esterase,
interleukin 1ß (IL-1ß), interleukin receptor 1 antagonist, tumor necrosis factor (TNF),
and eosinophilic cationic protein (ECP) biomarkers observed in the body in
inflammatory bowel diseases. It is reduced by giving the body β-glucan. At the same
time, the percentage of lymphocytes was decreased, and pathways for cytokine and
chemokine marking were developed. This review focuses on the therapeutic effect and
mechanism of β-glucan content derived from fungi, yeasts, and other organic sources
on inflammatory bowel disease (IBD) such as CD and UC, and irritable bowel
syndrome (IBS). 

Keywords: β-glucan, Crohn's Disease, Irritable Bowel Syndrome, Inflammatory Bowel Diseases, Ulcerative Colitis.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy